<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="33770d80-754f-11de-8dba-0002a5d5c51b"><labelDrug name="Benicar"><Normalization><mmtx cui="C1122245" preferredWord="Benicar" semType="phsu, orch"/></Normalization></labelDrug><generic name="olmesartan medoxomil"/><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.1" text="BENICAR (olmesartan medoxomil) tablet, film coated" type="negative"><entity charOffset="0:7" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.1.e.0" text="benicar" type="Biomedical_Entity"><Normalization><mmtx cui="C1122245" phraseText="BENICAR" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="9:29" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.1.e.1" text="olmesartan medoxomil" type="Biomedical_Entity"><Normalization><mmtx cui="C0386393" phraseText="(olmesartan medoxomil" preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.1.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.1.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4" lineNumber="7" text="Do not co-administer aliskiren with Benicar in patients with diabetes [see Drug Interactions (7 )]." type="regular"><entity charOffset="21:30" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.0" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with Benicar" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.1" text="Benicar" type="Drug"><Normalization><mmtx cui="C1122245" phraseText="aliskiren with Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.2" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes" preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes" preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><entity charOffset="0:20" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.3" text="Do not co-administer" type="Caution_Interaction"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.3"><relations><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.0"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.2" ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.1" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.4.e.3" type="Caution_Interaction"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.14" text="Drugs that act directly on the renin-angiotensin aldosterone system (RAAS) can have effects on the development of immature kidneys [see Use in Specific Populations (8.4)]." type="negative"><entity charOffset="37:48" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.14.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="directly on the renin-angiotensin aldosterone system (RAAS)" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="49:60" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.14.e.1" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="directly on the renin-angiotensin aldosterone system (RAAS)" preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.14.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.14.e.1"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16" text="In patients with an activated renin-angiotensin aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. " type="negative"><entity charOffset="36:47" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="with an activated renin-angiotensin aldosterone system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="48:59" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.1" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="with an activated renin-angiotensin aldosterone system," preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><entity charOffset="160:169" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.2" text="diuretics" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="treated with high doses of diuretics" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><entity charOffset="250:257" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.3" text="benicar" type="Biomedical_Entity"><Normalization><mmtx cui="C1122245" phraseText="with Benicar." preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.1"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.2"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.3"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.2"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.3"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.16.e.3"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21" text="As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Benicar. " type="negative"><entity charOffset="41:52" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="158:165" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.1" text="benicar" type="Biomedical_Entity"><Normalization><mmtx cui="C1122245" phraseText="treated with Benicar." preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="53:64" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.2" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.1"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.2"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.21.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" lineNumber="26" text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. " type="regular"><entity charOffset="176:222" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0" text="angiotensin converting enzyme (ACE) inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="treatment with angiotensin converting enzyme (ACE) inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="227:259" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1" text="angiotensin receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0815017" phraseText="angiotensin receptor antagonists" preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="285:293" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.2" text="oliguria" type="Specific_Interaction"><Normalization><mmtx cui="C0028961" phraseText="associated with oliguria" preferredWord="Oliguria" semType="sosy"/></Normalization></entity><entity charOffset="313:321" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.4" text="azotemia" type="Specific_Interaction"><Normalization><mmtx cui="C0242528" phraseText="progressive azotemia" preferredWord="Azotemia" semType="dsyn"/><mmtx cui="C0554309" phraseText="progressive azotemia" preferredWord="Prerenal uremia syndrome" semType="dsyn"/></Normalization></entity><entity charOffset="338:357" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.6" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="rarely with acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><entity charOffset="365:370" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.8" text="death" type="Specific_Interaction"/><entity charOffset="127:158" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10" text="severe congestive heart failure" type="SPAN"><Normalization><mmtx cui="C0018802" phraseText="patients with severe congestive heart failure" preferredWord="Congestive heart failure" semType="dsyn"/></Normalization></entity><entity charOffset="18:105" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11" text="renal function may depend upon the activity of the renin angiotensin-aldosterone system" type="SPAN"/><entity charOffset="285:293" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.12" text="oliguria" type="SPAN"><Normalization><mmtx cui="C0028961" phraseText="associated with oliguria" preferredWord="Oliguria" semType="sosy"/></Normalization></entity><entity charOffset="313:321" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.13" text="azotemia" type="SPAN"><Normalization><mmtx cui="C0242528" phraseText="progressive azotemia" preferredWord="Azotemia" semType="dsyn"/><mmtx cui="C0554309" phraseText="progressive azotemia" preferredWord="Prerenal uremia syndrome" semType="dsyn"/></Normalization></entity><entity charOffset="338:357" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.14" text="acute renal failure" type="SPAN"><Normalization><mmtx cui="C0022660" phraseText="rarely with acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><entity charOffset="365:370" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.15" text="death" type="SPAN"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.2"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.ddi.2"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.4"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.ddi.3"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.6"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.ddi.4"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.8"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.10, Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.11" ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.1" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23" lineNumber="26" text="Similar results may be anticipated in patients treated with Benicar [see Dosage and Administration (2.1), Drug Interactions (7), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]." type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="365:370" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.8" text="death" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="365:370" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.15" text="death" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="338:357" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.6" text="acute renal failure" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="338:357" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.14" text="acute renal failure" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="285:293" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.2" text="oliguria" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="285:293" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.12" text="oliguria" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="313:321" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.4" text="azotemia" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" Text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "/><anaphoraEntity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.0" text="Similar results" type="Expression"/><antecedentEntity charOffset="313:321" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.13" text="azotemia" type="SPAN"/></anaphoraRelation><entity charOffset="60:67" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.1" text="Benicar" type="Drug"><Normalization><mmtx cui="C1122245" phraseText="treated with Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="0:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.2" text="Similar results" type="Specific_Interaction"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22" text="In patients whose renal function may depend upon the activity of the renin angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. "><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.22.e.0"/></ellipsisSentence></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.23.e.1"/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.24" text="In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. " type="negative"><entity charOffset="132:136" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.24.e.0" text="urea" type="Biomedical_Entity"><Normalization><mmtx cui="C0041942" phraseText="blood urea nitrogen (BUN)" preferredWord="Urea" semType="bacs, phsu, orch"/><RxNorm RxCui="11002"/></Normalization></entity><entity charOffset="14:28" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.24.e.1" text="ace inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0003015" phraseText="of ACE inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.24.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.24.e.0"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72" text="No significant drug interactions were reported in studies in which Benicar was co-administered with digoxin or warfarin in healthy volunteers." type="negative"><entity charOffset="100:107" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.0" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="co-administered with digoxin" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="111:119" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin in healthy volunteers." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="67:74" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.2" text="benicar" type="Biomedical_Entity"><Normalization><mmtx cui="C1122245" phraseText="in which Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.1"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.0"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.72.e.1"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73" text="The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)3/Mg(OH)2]." type="negative"><entity charOffset="110:117" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.0" text="mg 2" type="Biomedical_Entity"><Normalization><mmtx cui="C2346927" phraseText="[Al(OH)3/Mg(OH)2" preferredWord="Magnesium Cation" semType="phsu, elii"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="23:33" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.1" text="olmesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0386393" phraseText="The bioavailability of olmesartan" preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="92:100" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.2" text="antacids" type="Biomedical_Entity"><Normalization><mmtx cui="C0003138" phraseText="altered by the co-administration of antacids" preferredWord="Antacids" semType="phsu"/><RxNorm RxCui="863"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.0"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.0"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.73.e.2"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76" text="Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)" type="negative"><entity charOffset="88:104" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.0" text="cox-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="(COX-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="382306"/></Normalization></entity><entity charOffset="59:86" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.1" text="cyclooxygenase-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="Selective Cyclooxygenase-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="119049"/></Normalization></entity><entity charOffset="0:38" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.2" text="non-steroidal anti-inflammatory agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003211" phraseText="Non-Steroidal Anti-Inflammatory Agents" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="1005832"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.0"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.76.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77" lineNumber="89" text="In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure. " type="regular"><entity charOffset="20:27" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.0" text="elderly" type="SPAN"/><entity charOffset="29:44" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.1" text="volume-depleted" type="SPAN"/><entity charOffset="65:81" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.2" text="diuretic therapy" type="SPAN"/><entity charOffset="92:118" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.3" text="compromised renal function" type="SPAN"/><entity charOffset="141:147" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.4" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="co-administration of NSAIDs," preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="159:185" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.5" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors," preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="192:227" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.7" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="239:259" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.8" text="olmesartan medoxomil" type="Drug"><Normalization><mmtx cui="C0386393" phraseText="olmesartan medoxomil," preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="275:306" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.10" text="deterioration of renal function" type="Specific_Interaction"/><entity charOffset="327:346" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.12" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="possible acute renal failure." preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><classClassMembership drugClass="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.5"/><drugClassMembership drug="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.8" drugClass="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.7"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.10"><relations><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.7"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.4"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.2"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.ddi.2"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.12"><relations><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.7"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.4"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.2"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.1"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.0, Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.2, Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.3, Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.1" ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.4" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.7" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.77.e.10" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79" lineNumber="89" text="Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy." type="regular"><entity charOffset="0:7" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.0" text="Monitor" type="Caution_Interaction"/><entity charOffset="58:78" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.2" text="olmesartan medoxomil" type="Drug"><Normalization><mmtx cui="C0386393" phraseText="olmesartan medoxomil" preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="83:88" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.3" text="NSAID" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAID therapy." preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.79.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80" lineNumber="91" text="The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors." type="regular"><entity charOffset="31:66" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.0" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="The antihypertensive effect of angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="78:98" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1" text="olmesartan medoxomil" type="Drug"><Normalization><mmtx cui="C0386393" phraseText="olmesartan medoxomil" preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="120:126" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.3" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="attenuated by NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="137:163" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.4" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors." preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="4:27|106:116" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.6" text="antihypertensive effect attenuated" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1" drugClass="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.0"/><classClassMembership drugClass="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.4"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.6" type="Specific_Interaction"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81" text="Dual Blockade of the Renin-Angiotensin System (RAS)" type="negative"><entity charOffset="5:13" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81.e.0" text="blockade" type="Biomedical_Entity"><Normalization><mmtx cui="C3540676" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Blockade" semType="phsu"/><RxNorm RxCui="1423936"/></Normalization></entity><entity charOffset="27:38" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82" lineNumber="95" text="Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. " type="irregular"><entity charOffset="30:59" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0" text="angiotensin receptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><mmtx cui="C0815017" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="61:75" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="80:89" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="128:139" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.3" text="hypotension" type="Specific_Interaction"/><entity charOffset="141:153" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.5" text="hyperkalemia" type="Specific_Interaction"/><entity charOffset="159:184" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.7" text="changes in renal function" type="Specific_Interaction"/><entity charOffset="196:215" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.9" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80" text="The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1"/></ellipsisSentence><middleSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.ddi.2"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80" text="The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1"/></ellipsisSentence><middleSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.ddi.3"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.7"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80" text="The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1"/></ellipsisSentence><middleSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.ddi.4"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.9"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80" text="The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.80.e.1"/></ellipsisSentence><middleSentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.81" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.1"/><pair ddi="true" e1="labelDrug" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.82.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83" lineNumber="95" text="Closely monitor blood pressure, renal function and electrolytes in patients on Benicar and other agents that affect the RAS." type="regular"><entity charOffset="8:15" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.0" text="monitor" type="Caution_Interaction"/><entity charOffset="79:86" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.2" text="Benicar" type="Drug"><Normalization><mmtx cui="C1122245" phraseText="on Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="97:123" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.3" text="agents that affect the RAS" type="Drug_Class"><Normalization><mmtx cui="C1254351" phraseText="other agents" preferredWord="Pharmacologic Substance" semType="phsu"/><RxNorm RxCui="126263"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.0"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.83.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84" lineNumber="97" text="Do not co-administer aliskiren with Benicar in patients with diabetes [see Contraindications (4)]. " type="regular"><entity charOffset="0:20" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.0" text="Do not co-administer" type="Caution_Interaction"/><entity charOffset="21:30" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with Benicar" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.3" text="Benicar" type="Drug"><Normalization><mmtx cui="C1122245" phraseText="aliskiren with Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.4" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes" preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes" preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.0"><relations><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.4" ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.84.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85" lineNumber="97" text="Avoid use of aliskiren with Benicar in patients with renal impairment (GFR &lt;60 ml/min)." type="regular"><entity charOffset="0:9" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.0" text="Avoid use" type="Caution_Interaction"/><entity charOffset="13:22" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="use of aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="28:35" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.3" text="Benicar" type="Drug"><Normalization><mmtx cui="C1122245" phraseText="with Benicar" preferredWord="Benicar" semType="phsu, orch"/><RxNorm RxCui="327503"/></Normalization></entity><entity charOffset="53:69" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.4" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.0"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.2"/></relation><relation type="hasContext"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.4" ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.85.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87" lineNumber="101" text="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. " type="regular"><entity charOffset="29:57" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.0" text="bile acid sequestering agent" type="Drug_Class"><Normalization><mmtx cui="C2917673" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Bile Acid [EPC]" semType="phsu"/><mmtx cui="C1254351" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Pharmacologic Substance" semType="phsu"/><mmtx cui="C0360087" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Bile agent" semType="phsu, orch"/><mmtx cui="C0001128" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Acids" semType="chem"/><RxNorm RxCui="1540"/></Normalization></entity><entity charOffset="58:83" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1" text="colesevelam hydrochloride" type="Drug"><Normalization><mmtx cui="C0541154" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Colesevelam hydrochloride" semType="phsu, orch"/><mmtx cui="C0541154" phraseText="Concurrent administration of bile acid sequestering agent colesevelam hydrochloride" preferredWord="Colesevelam hydrochloride" semType="phsu, orch"/><RxNorm RxCui="141625"/></Normalization></entity><entity charOffset="147:157" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.3" text="olmesartan" type="Drug"><Normalization><mmtx cui="C0386393" phraseText="peak plasma concentration of olmesartan." preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><mmtx cui="C1098320" phraseText="peak plasma concentration of olmesartan." preferredWord="olmesartan" semType="phsu, orch"/><mmtx cui="C0386393" phraseText="peak plasma concentration of olmesartan." preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><mmtx cui="C1098320" phraseText="peak plasma concentration of olmesartan." preferredWord="olmesartan" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="84:113" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.4" text="reduces the systemic exposure" type="Decrease_Interaction"/><entity charOffset="84:95|123:143" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.6" text="reduces the plasma concentration" type="Decrease_Interaction"/><drugClassMembership drug="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1" drugClass="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.0"/><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.4"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.ddi.2"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.6"><relations><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.1" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.87.e.4" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.88" text="Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. " type="negative"><entity charOffset="18:28" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.88.e.0" text="olmesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C1098320" phraseText="Administration of olmesartan" preferredWord="olmesartan" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="55:80" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.88.e.1" text="colesevelam hydrochloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0541154" phraseText="prior to colesevelam hydrochloride" preferredWord="Colesevelam hydrochloride" semType="phsu, orch"/><RxNorm RxCui="141625"/></Normalization></entity><pair ddi="false" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.88.e.0" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.88.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89" lineNumber="101" text="Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose [see Clinical Pharmacology (12.3)]." type="regular"><entity charOffset="9:22|51:57" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.0" text="administering before" type="Caution_Interaction"/><entity charOffset="23:33" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.2" text="olmesartan" type="Drug"><Normalization><mmtx cui="C0386393" phraseText="administering olmesartan at least 4 hours" preferredWord="Olmesartan medoxomil" semType="phsu, orch"/><mmtx cui="C1098320" phraseText="administering olmesartan at least 4 hours" preferredWord="olmesartan" semType="phsu, orch"/><RxNorm RxCui="321064"/></Normalization></entity><entity charOffset="62:87" id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.3" text="colesevelam hydrochloride" type="Drug"><Normalization><mmtx cui="C0541154" phraseText="before the colesevelam hydrochloride dose" preferredWord="Colesevelam hydrochloride" semType="phsu, orch"/><RxNorm RxCui="141625"/></Normalization></entity><drugInteraction id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.ddi.1"><interaction trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.2" e2="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.3" trigger="Dailymed.33770d80-754f-11de-8dba-0002a5d5c51b.s.89.e.0" type="Caution_Interaction"/></sentence><positiveExamples number="13"/><negativeExamples number="25"/></document>